CoChat

Long-term effects of growth hormone replacement therapy in childhood-onset craniopharyngioma: results of the German Craniopharyngioma Registry (HIT-Endo)

Boekhoff, Svenja, Bogusz, Agnieszka, Sterkenburg, Anthe S, Eveslage, Maria, Müller, Hermann L · 2018 · European Journal of Endocrinology
Cited by 65

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Objective: Quality of survival, prognosis and long-term outcome are often severely impaired in childhood-onset craniopharyngioma (CP) patients. Identification of risk factors for sequelae such as growth hormone (GH) deficiency is important for appropriate treatment and rehabilitation. Design: In a cross-sectional study, 79 CP patients recruited in HIT-Endo before 2000 were analyzed according to GH substitution: (a) CP never GH treated (noGH); (b) CP GH treated only during childhood (pedGH); (c) CP under GH, initiated at adulthood (adultGH); (d) CP under GH during childhood and continued during adulthood (contGH). Methods: Progression-free (PFS) and overall survival (OS), height, BMI, psychosocial and neuropsychological status (EORTC QLQ-C30, MFI-20). Results: OS and PFS rates were similar in all subgroups. ContGH and pedGH CP presented with increases in height (P = 0.002;P = 0.0001) during long-term follow-up when compared with baseline. In all subgroups except for pedGH, increases in BMI were observed when compared with BMI at diagnosis. For emotional functionality and physical fatigue, adultGH CP showed worse (P = 0.037;P = 0.034) response (mean: 61.4%; 12.5%) when compared with pedGH CP (mean: 83.5%; 7.7%). Observed differences were not related to irradiation and hypothalamic involvement. In terms of psychosocial status, no differences were observed between subgroups. Conclusions: We conclude that GH substitution was safe with regard to risk of tumor progression/relapse in CP. Growth was improved by GH, whereas the development of obesity was not influenced by GH substitution. However, early initiation of GH substitution after CP diagnosis might have beneficial effects on weight development and neuropsychological outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje-18-0505

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 115

  1. 2014, Long-term outcomes and complications in patients with craniopharyngioma: the British Columbia Cancer Agency experience, International Journal of Radiation Oncology, Biology, Physics, 88, 1011, 10.1016/j.ijrobp.2014.01.019 · DOI
  2. 2003, Improvements in final height over 25 years in Growth Hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement, Journal of Clinical Endocrinology and Metabolism, 88, 3682, 10.1210/jc.2003-030366 · DOI · Paper page
  3. 2002, Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status – 3-year results from the HypoCCS Database, Journal of Clinical Endocrinology and Metabolism, 87, 1600
  4. 2011, Consequences of craniopharyngioma surgery in children, Journal of Clinical Endocrinology and Metabolism, 96, 1981, 10.1210/jc.2011-0174 · DOI · Paper page
  5. 2014, Childhood craniopharyngioma – changes of treatment strategies in the trials KRANIOPHARYNGEOM 2000/2007, Klinische Padiatrie, 226, 161, 10.1055/s-0034-1368785 · DOI · Paper page
  6. 2018, Craniopharyngioma – a chronic disease, Swiss Medical Weekly, 148, w14548
  7. 2015, Eating behavior, weight problems and eating disorders in 101 long-term survivors of childhood-onset craniopharyngioma, Journal of Pediatric Endocrinology and Metabolism, 28, 35
  8. 2010, Health status in long-term survivors of pediatric craniopharyngiomas, Journal of Neuroscience Nursing, 42, 323, 10.1097/JNN.0b013e3181f8a59d · DOI · Paper page
  9. 2005, The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma, European Journal of Endocrinology, 152, 557, 10.1530/eje.1.01877 · DOI · Paper page
  10. 2015, Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden, Journal of Clinical Endocrinology and Metabolism, 100, 467, 10.1210/jc.2014-3525 · DOI · Paper page
  11. 2009, Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy, European Journal of Endocrinology, 161, 671, 10.1530/EJE-09-0449 · DOI · Paper page
  12. 2006, Relapse pattern after complete resection and early progression after incomplete resection of childhood craniopharyngioma, Klinische Padiatrie, 218, 315, 10.1055/s-2006-942249 · DOI · Paper page
  13. 1996, Obesity in childhood craniopharyngioma: relation to post-operative hypothalamic damage shown by magnetic resonance imaging, Journal of Clinical Endocrinology and Metabolism, 81, 2734
  14. 2010, Childhood craniopharyngioma – current concepts in diagnosis, therapy and follow-up, Nature Reviews Endocrinology, 6, 609, 10.1038/nrendo.2010.168 · DOI · Paper page
  15. 2018, Relative risks of contributing factors to morbidity and mortality in adults with craniopharyngioma on Growth Hormone replacement, Journal of Clinical Endocrinology and Metabolism, 103, 768, 10.1210/jc.2017-01542 · DOI · Paper page
  16. 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, Journal of the National Cancer Institute, 85, 365, 10.1093/jnci/85.5.365 · DOI · Paper page
  17. 2011, Long-term clinical outcomes following treatment of childhood craniopharyngioma, Pediatric Blood and Cancer, 56, 1120, 10.1002/pbc.22884 · DOI · Paper page
  18. 2003, Functional capacity, obesity and hypothalamic involvement: cross-sectional study on 212 patients with childhood craniopharyngioma, Klinische Padiatrie, 215, 310, 10.1055/s-2003-45499 · DOI · Paper page
  19. 2001, A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices, Journal of Clinical Endocrinology and Metabolism, 86, 4657, 10.1210/jcem.86.10.7887 · doi:10.1210/jcem.86.10.7887 · Paper page
  20. 2015, Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes, Neuro-Oncology, 17, 1029, 10.1093/neuonc/nov044 · DOI · Paper page
  21. 1998, Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence, Journal of Clinical Endocrinology and Metabolism, 83, 3897
  22. 2014, Childhood craniopharyngioma – changes of treatment strategies in the trials KRANIOPHARYNGEOM 2000/2007, Klinische Padiatrie, 226, 161, 10.1055/s-0034-1368785 · DOI · Paper page
  23. 2014, Craniopharyngioma, Endocrine Reviews, 35, 513, 10.1210/er.2013-1115 · DOI · Paper page
  24. 2013, Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction, European Journal of Endocrinology, 169, 511, 10.1530/EJE-13-0280 · DOI · Paper page
  25. 2018, Relative risks of contributing factors to morbidity and mortality in adults with craniopharyngioma on Growth Hormone replacement, Journal of Clinical Endocrinology and Metabolism, 103, 768, 10.1210/jc.2017-01542 · DOI · Paper page
  26. 2001, Obesity after childhood craniopharyngioma – German multicenter study on pre-operative risk factors and quality of life, Klinische Padiatrie, 213, 244, 10.1055/s-2001-16855 · DOI · Paper page
  27. 2011, Consequences of craniopharyngioma surgery in children, Journal of Clinical Endocrinology and Metabolism, 96, 1981, 10.1210/jc.2011-0174 · DOI · Paper page
  28. 2013, Childhood craniopharyngioma, Pituitary, 16, 56, 10.1007/s11102-012-0401-0 · DOI
  29. 2010, Analyses of treatment variables for patients with childhood craniopharyngioma – results of the multicenter prospective trial KRANIOPHARYNGEOM 2000 after three years of follow-up, Hormone Research in Paediatrics, 73, 175, 10.1159/000284358 · DOI · Paper page
  30. 2011, Improvements in behaviour and self-esteem following Growth Hormone treatment in short prepubertal children, Hormone Research in Paediatrics, 75, 291, 10.1159/000322937 · DOI · Paper page
  31. 2018, The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up, European Journal of Endocrinology, 178, 11, 10.1530/EJE-17-0387 · DOI · Paper page
  32. 1998, Efficacy and safety of Growth Hormone treatment in children with prior craniopharyngioma: an analysis of the Pharmacia and Upjohn International Growth Database (KIGS) from 1988 to 1996, Hormone Research, 49, 91, 10.1159/000023133 · DOI · Paper page
  33. 2014, Neuropsychological outcome in patients with childhood craniopharyngioma and hypothalamic involvement, Jurnalul Pediatrului, 164, 876.e874
  34. 2017, Patterns of care and treatment outcomes of patients with craniopharyngioma in the national cancer database, Journal of Neuro-Oncology, 132, 109, 10.1007/s11060-016-2342-3 · DOI
  35. 2016, Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study, Journal of Neurosurgery: Pediatrics, 18, 408
  36. 1996, Obesity in childhood craniopharyngioma: relation to post-operative hypothalamic damage shown by magnetic resonance imaging, Journal of Clinical Endocrinology and Metabolism, 81, 2734
  37. 2015, Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden, Journal of Clinical Endocrinology and Metabolism, 100, 467, 10.1210/jc.2014-3525 · DOI · Paper page
  38. 2002, Craniopharyngioma in adults and children: a study of 122 surgical cases, Journal of Neurological Surgery, 97, 3
  39. 2011, Long-term clinical outcomes following treatment of childhood craniopharyngioma, Pediatric Blood and Cancer, 56, 1120, 10.1002/pbc.22884 · DOI · Paper page
  40. 2017, Very long-term sequelae of craniopharyngioma, European Journal of Endocrinology, 176, 755, 10.1530/EJE-17-0044 · DOI · Paper page
  41. 2001, Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset: a comparative, prospective study, Journal of Clinical Endocrinology and Metabolism, 86, 4693, 10.1210/jcem.86.10.7896 · doi:10.1210/jcem.86.10.7896 · Paper page
  42. 2013, Childhood craniopharyngioma, Pituitary, 16, 56, 10.1007/s11102-012-0401-0 · DOI
  43. 2014, Long-term outcomes and complications in patients with craniopharyngioma: the British Columbia Cancer Agency experience, International Journal of Radiation Oncology, Biology, Physics, 88, 1011, 10.1016/j.ijrobp.2014.01.019 · DOI
  44. 1998, Efficacy and safety of Growth Hormone treatment in children with prior craniopharyngioma: an analysis of the Pharmacia and Upjohn International Growth Database (KIGS) from 1988 to 1996, Hormone Research, 49, 91, 10.1159/000023133 · DOI · Paper page
  45. 2003, Functional capacity, obesity and hypothalamic involvement: cross-sectional study on 212 patients with childhood craniopharyngioma, Klinische Padiatrie, 215, 310, 10.1055/s-2003-45499 · DOI · Paper page
  46. 2005, Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up, Clinical Endocrinology, 62, 397, 10.1111/j.1365-2265.2005.02231.x · DOI · Paper page
  47. 2002, Craniopharyngioma: the St. Jude Children’s Research Hospital experience 1984–2001, International Journal of Radiation Oncology, Biology, Physics, 53, 533, 10.1016/S0360-3016(02)02799-2 · DOI · Paper page
  48. 2018, Self- and informant-rated apathy in patients with childhood-onset craniopharyngioma, Journal of Neuro-Oncology
  49. 2002, Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status – 3-year results from the HypoCCS Database, Journal of Clinical Endocrinology and Metabolism, 87, 1600
  50. 2003, Improvements in final height over 25 years in Growth Hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement, Journal of Clinical Endocrinology and Metabolism, 88, 3682, 10.1210/jc.2003-030366 · DOI · Paper page
  51. 2010, Health status in long-term survivors of pediatric craniopharyngiomas, Journal of Neuroscience Nursing, 42, 323, 10.1097/JNN.0b013e3181f8a59d · DOI · Paper page
  52. 2011, Neurosurgical treatment of craniopharyngioma in adults and children: early and long-term results in a large case series, Journal of Neurological Surgery, 114, 1350
  53. 2001, Obesity after childhood craniopharyngioma – German multicenter study on pre-operative risk factors and quality of life, Klinische Padiatrie, 213, 244, 10.1055/s-2001-16855 · DOI · Paper page
  54. 2004, Outcome of craniopharyngioma in children: long-term complications and quality of life, Developmental Medicine and Child Neurology, 46, 220, 10.1111/j.1469-8749.2004.tb00476.x · DOI · Paper page
  55. 2005, High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma, Clinical Endocrinology, 62, 197, 10.1111/j.1365-2265.2004.02196.x · DOI · Paper page
  56. 2014, Craniopharyngioma, Endocrine Reviews, 35, 513, 10.1210/er.2013-1115 · DOI · Paper page
  57. 2018, Craniopharyngioma – a chronic disease, Swiss Medical Weekly, 148, w14548
  58. 2004, Outcome of craniopharyngioma in children: long-term complications and quality of life, Developmental Medicine and Child Neurology, 46, 220, 10.1111/j.1469-8749.2004.tb00476.x · DOI · Paper page
  59. 2010, Analyses of treatment variables for patients with childhood craniopharyngioma – results of the multicenter prospective trial KRANIOPHARYNGEOM 2000 after three years of follow-up, Hormone Research in Paediatrics, 73, 175, 10.1159/000284358 · DOI · Paper page
  60. 2017, Very long-term sequelae of craniopharyngioma, European Journal of Endocrinology, 176, 755, 10.1530/EJE-17-0044 · DOI · Paper page
  61. 2011, Improvements in behaviour and self-esteem following Growth Hormone treatment in short prepubertal children, Hormone Research in Paediatrics, 75, 291, 10.1159/000322937 · DOI · Paper page
  62. 2012, Markers of recurrence and long-term morbidity in craniopharyngioma: a systematic analysis of 171 patients, Journal of Clinical Endocrinology and Metabolism, 97, 1258, 10.1210/jc.2011-2817 · DOI · Paper page
  63. 2012, Hypothalamic obesity in children, Obesity Reviews, 13, 780, 10.1111/j.1467-789X.2012.01004.x · DOI · Paper page
  64. 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, Journal of the National Cancer Institute, 85, 365, 10.1093/jnci/85.5.365 · DOI · Paper page
  65. 2013, Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction, European Journal of Endocrinology, 169, 511, 10.1530/EJE-13-0280 · DOI · Paper page
  66. 2006, Relapse pattern after complete resection and early progression after incomplete resection of childhood craniopharyngioma, Klinische Padiatrie, 218, 315, 10.1055/s-2006-942249 · DOI · Paper page
  67. 2005, High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma, Clinical Endocrinology, 62, 197, 10.1111/j.1365-2265.2004.02196.x · DOI · Paper page
  68. 2001, A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices, Journal of Clinical Endocrinology and Metabolism, 86, 4657, 10.1210/jcem.86.10.7887 · doi:10.1210/jcem.86.10.7887 · Paper page
  69. 2004, Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults, International Journal of Radiation Oncology, Biology, Physics, 58, 714, 10.1016/S0360-3016(03)01570-0 · DOI · Paper page
  70. 2005, Craniopharyngiomas in children: surgical experience at Children’s Memorial Hospital, Child’s Nervous System, 21, 729, 10.1007/s00381-005-1202-9 · DOI · Paper page
  71. 2015, Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes, Neuro-Oncology, 17, 1029, 10.1093/neuonc/nov044 · DOI · Paper page
  72. 2018, Self- and informant-rated apathy in patients with childhood-onset craniopharyngioma, Journal of Neuro-Oncology
  73. 2012, Markers of recurrence and long-term morbidity in craniopharyngioma: a systematic analysis of 171 patients, Journal of Clinical Endocrinology and Metabolism, 97, 1258, 10.1210/jc.2011-2817 · DOI · Paper page
  74. 2018, Excess morbidity and mortality in patients with craniopharyngioma: a hospital-based retrospective cohort study, European Journal of Endocrinology, 178, 95
  75. 2018, The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up, European Journal of Endocrinology, 178, 11, 10.1530/EJE-17-0387 · DOI · Paper page
  76. 2009, Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy, European Journal of Endocrinology, 161, 671, 10.1530/EJE-09-0449 · DOI · Paper page
  77. 2006, Growth Hormone treatment and risk of second neoplasms in the childhood cancer survivor, Journal of Clinical Endocrinology and Metabolism, 91, 3494, 10.1210/jc.2006-0656 · DOI · Paper page
  78. 2018, Quality of life and growth after childhood craniopharyngioma: results of the multinational trial KRANIOPHARYNGEOM 2007, Endocrine, 59, 364, 10.1007/s12020-017-1489-9 · DOI · Paper page
  79. 2011, Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up, European Journal of Endocrinology, 165, 17, 10.1530/EJE-11-0158 · DOI · Paper page
  80. 2002, Craniopharyngioma in adults and children: a study of 122 surgical cases, Journal of Neurological Surgery, 97, 3
  81. 2004, Features of the metabolic syndrome after childhood craniopharyngioma, Journal of Clinical Endocrinology and Metabolism, 89, 81, 10.1210/jc.2003-030442 · DOI · Paper page
  82. 2005, Craniopharyngiomas in children: surgical experience at Children’s Memorial Hospital, Child’s Nervous System, 21, 729, 10.1007/s00381-005-1202-9 · DOI · Paper page
  83. 1991, Body mass index variations: centiles from birth to 87 years, European Journal of Clinical Nutrition, 45, 13
  84. 2008, Hypothalamic obesity: causes, consequences, treatment, Pediatric Endocrinology Reviews, 6, 220
  85. 1993, 20-year experience in childhood craniopharyngioma, International Journal of Radiation Oncology, Biology, Physics, 27, 189, 10.1016/0360-3016(93)90227-M · DOI · Paper page
  86. 2018, Excess morbidity and mortality in patients with craniopharyngioma: a hospital-based retrospective cohort study, European Journal of Endocrinology, 178, 95
  87. 2018, Quality of life and growth after childhood craniopharyngioma: results of the multinational trial KRANIOPHARYNGEOM 2007, Endocrine, 59, 364, 10.1007/s12020-017-1489-9 · DOI · Paper page
  88. 1998, Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence, Journal of Clinical Endocrinology and Metabolism, 83, 3897
  89. 2017, The neuroendocrine sequelae of paediatric craniopharyngioma: a 40-year meta-data analysis of 185 cases from three UK centres, European Journal of Endocrinology, 176, 359, 10.1530/EJE-16-0812 · DOI · Paper page
  90. 2015, Eating behavior, weight problems and eating disorders in 101 long-term survivors of childhood-onset craniopharyngioma, Journal of Pediatric Endocrinology and Metabolism, 28, 35
  91. 2016, Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study, Journal of Neurosurgery: Pediatrics, 18, 408
  92. 2012, Hypothalamic obesity in children, Obesity Reviews, 13, 780, 10.1111/j.1467-789X.2012.01004.x · DOI · Paper page
  93. 2017, New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma, Nature Reviews Endocrinology, 13, 299, 10.1038/nrendo.2016.217 · DOI · Paper page
  94. 1989, Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development, Helvetica Paediatrica Acta: Supplementum, 52, 1
  95. 2006, Growth Hormone treatment and risk of second neoplasms in the childhood cancer survivor, Journal of Clinical Endocrinology and Metabolism, 91, 3494, 10.1210/jc.2006-0656 · DOI · Paper page
  96. 1994, Surgery, radiation, and combination therapy in the treatment of childhood craniopharyngioma – a 20-year experience, Pediatric Neurosurgery, 21, 75, 10.1159/000120866 · DOI
  97. 2011, Neurosurgical treatment of craniopharyngioma in adults and children: early and long-term results in a large case series, Journal of Neurological Surgery, 114, 1350
  98. 2004, Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults, International Journal of Radiation Oncology, Biology, Physics, 58, 714, 10.1016/S0360-3016(03)01570-0 · DOI · Paper page
  99. 2001, Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset: a comparative, prospective study, Journal of Clinical Endocrinology and Metabolism, 86, 4693, 10.1210/jcem.86.10.7896 · doi:10.1210/jcem.86.10.7896 · Paper page
  100. 2012, Xanthogranuloma, Rathke’s cyst, and childhood craniopharyngioma: results of prospective multinational studies of children and adolescents with rare sellar malformations, Journal of Clinical Endocrinology and Metabolism, 97, 3935, 10.1210/jc.2012-2069 · DOI · Paper page
  101. 2011, Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up, European Journal of Endocrinology, 165, 17, 10.1530/EJE-11-0158 · DOI · Paper page
  102. 2004, Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma, Journal of Clinical Endocrinology and Metabolism, 89, 3298, 10.1210/jc.2003-031751 · DOI · Paper page
  103. 1993, 20-year experience in childhood craniopharyngioma, International Journal of Radiation Oncology, Biology, Physics, 27, 189, 10.1016/0360-3016(93)90227-M · DOI · Paper page
  104. 2017, New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma, Nature Reviews Endocrinology, 13, 299, 10.1038/nrendo.2016.217 · DOI · Paper page
  105. 1989, Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development, Helvetica Paediatrica Acta: Supplementum, 52, 1
  106. 2010, Childhood craniopharyngioma – current concepts in diagnosis, therapy and follow-up, Nature Reviews Endocrinology, 6, 609, 10.1038/nrendo.2010.168 · DOI · Paper page
  107. 2005, The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma, European Journal of Endocrinology, 152, 557, 10.1530/eje.1.01877 · DOI · Paper page
  108. 1995, The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue, Journal of Psychosomatic Research, 39, 315, 10.1016/0022-3999(94)00125-O · DOI · Paper page
  109. 2008, Hypothalamic obesity: causes, consequences, treatment, Pediatric Endocrinology Reviews, 6, 220
  110. 1994, Surgery, radiation, and combination therapy in the treatment of childhood craniopharyngioma – a 20-year experience, Pediatric Neurosurgery, 21, 75, 10.1159/000120866 · DOI
  111. 2017, The neuroendocrine sequelae of paediatric craniopharyngioma: a 40-year meta-data analysis of 185 cases from three UK centres, European Journal of Endocrinology, 176, 359, 10.1530/EJE-16-0812 · DOI · Paper page
  112. 1991, Body mass index variations: centiles from birth to 87 years, European Journal of Clinical Nutrition, 45, 13
  113. 2002, Craniopharyngioma: the St. Jude Children’s Research Hospital experience 1984–2001, International Journal of Radiation Oncology, Biology, Physics, 53, 533, 10.1016/S0360-3016(02)02799-2 · DOI · Paper page
  114. 1995, The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue, Journal of Psychosomatic Research, 39, 315, 10.1016/0022-3999(94)00125-O · DOI · Paper page
  115. 2017, Patterns of care and treatment outcomes of patients with craniopharyngioma in the national cancer database, Journal of Neuro-Oncology, 132, 109, 10.1007/s11060-016-2342-3 · DOI

Cited by

See all 65

Metadata

Authors
Boekhoff, S., Bogusz, A., Sterkenburg, A. S., Eveslage, M., & Müller, H. L.
Affiliations
  • 1Department of Pediatrics and Pediatric Hematology/Oncology, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany
  • 4Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany
Venue
European Journal of Endocrinology
Published
2018-11
Volume
179
Issue
5
Pages
331-341
ISSN
  • 0804-4643
  • 1479-683X
Cited by
65
References
5

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.